Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
暂无分享,去创建一个
Klaus Klaushofer | Piet Geusens | Regis O'Keefe | Bo Abrahamsen | T. Brown | P. Geusens | H. Genant | D. Burr | R. O’Keefe | K. Koval | D. Dempster | E. Shane | P. Ebeling | A. Cheung | R. Weinstein | T. Einhorn | J. Curtis | M. Whyte | M. V. D. van der Meulen | J. Lane | B. Abrahamsen | J. Nieves | F. Cosman | K. Klaushofer | Elizabeth Shane | David Burr | Felicia Cosman | Richard Dell | Fergus McKiernan | Ross McKinney | Alvin Ng | Jeri Nieves | Socrates Papapoulos | S. Papapoulos | F. McKiernan | Robert A. Adler | R. Dell | Ross E. McKinney | A. Ng | H. T. Sen | Robert S Weinstein | Kenneth Koval | Harry K Genant | Angela M Cheung | Jeffrey R Curtis | Peter R Ebeling | Robert A Adler | Thomas D Brown | David Dempster | Thomas A Einhorn | Joseph M Lane | Howe Tet Sen | Marjolein CH van der Meulen | Michael Whyte | R. Adler
[1] J. Schneider. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. , 2006, Geriatrics.
[2] A. Ivković,et al. Stress fractures of the femoral shaft in athletes: a new treatment algorithm , 2006, British Journal of Sports Medicine.
[3] S. Boonen,et al. Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] R. Keller,et al. Basic Epidemiology of Fractures of the Upper and Lower Limb among Americans over 65 Years of Age , 1996, Epidemiology.
[5] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[6] G. Li,et al. Radiographic and histologic analyses of stress fracture in rabbit tibias. , 1985, The American journal of sports medicine.
[7] F. S. Chew,et al. Subtrochanteric Femoral Insufficiency Fracture Following Bisphosphonate Therapy for Osseous Metastases , 2015, Radiology case reports.
[8] I. Harris,et al. FEMORAL INSUFFICIENCY FRACTURES ASSOCIATED WITH PROLONGED ALENDRONATE THERAPY , 2012 .
[9] F. Bandeira,et al. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. , 2011, The Journal of clinical endocrinology and metabolism.
[10] D. Black,et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. , 2011, The Journal of clinical endocrinology and metabolism.
[11] M. Hameed,et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. , 2011, The Journal of bone and joint surgery. American volume.
[12] P. C. Wong. Fracture Epidemiology in a Mixed Southeastern Asian Community (Singapore) , 1966, Clinical orthopaedics and related research.
[13] B. Clarke,et al. Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial , 2011 .
[14] C. Cooper,et al. Excess mortality following hip fracture: a systematic epidemiological review , 2009, Osteoporosis International.
[15] D. Burr,et al. Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] David B. Burr,et al. Experimental stress fractures of the tibia: biological and mechanical aetiology in rabbits , 1990, The Journal of bone and joint surgery. British volume.
[17] D. Burr,et al. Raloxifene enhances vertebral mechanical properties independent of bone density. , 2006, Bone.
[18] G. Husada,et al. Bilateral Mid-Diaphyseal Femoral Stress Fractures in the Elderly , 2005, European Journal of Trauma.
[19] D. Lorich,et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] M. Gebhart,et al. Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy , 2010, Clinical orthopaedics and related research.
[21] K. Mchale,et al. Case Reports: Treatment of Subtrochanteric and Ipsilateral Femoral Neck Fractures in an Adult with Osteopetrosis , 2008, Clinical orthopaedics and related research.
[22] R. Eastell,et al. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. , 2010, The Journal of clinical endocrinology and metabolism.
[23] M. Saito,et al. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus , 2010, Osteoporosis International.
[24] T. Howe,et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? , 2008, Injury.
[25] S. Vasikaran,et al. Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[26] H. Altundal,et al. The effect of alendronate on resorption of the alveolar bone following tooth extraction. , 2004, International journal of oral and maxillofacial surgery.
[27] Matthew J. Silva,et al. Skeletal Self‐Repair : Stress Fracture Healing by Rapid Formation and Densification of Woven Bone , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] E. Dicarlo,et al. Case Report of Spontaneous, Nonspinal Fractures in a Multiple Myeloma Patient on Long-term Pamidronate and Zoledronic Acid , 2008, HSS Journal.
[29] Jiliang Li,et al. Imaging bone microdamage in vivo with positron emission tomography. , 2005, Bone.
[30] P. Fratzl,et al. Bone mineralization density distribution in health and disease. , 2008, Bone.
[31] A. Davies,et al. Magnetic resonance imaging appearances of fatigue fractures of the long bones of the lower limb. , 1994, The British journal of radiology.
[32] D. Vashishth. Advanced Glycation End-products and Bone Fractures. , 2009, IBMS boneKEy.
[33] M. Swiontkowski. Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2009 .
[34] M. Saito,et al. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs , 2008, Osteoporosis International.
[35] M. Ahlman,et al. Evolution of bisphosphonate‐related atypical fracture retrospectively observed with DXA scanning , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[36] Matthew R Allen,et al. Human femoral neck has less cellular periosteum, and more mineralized periosteum, than femoral diaphyseal bone. , 2005, Bone.
[37] Jiliang Li,et al. The Histological Appearance of Stress Fractures , 2000 .
[38] T. Chow,et al. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. , 2007, Hong Kong medical journal = Xianggang yi xue za zhi.
[39] O. Böstman,et al. Specific features associated with femoral shaft fractures caused by low-energy trauma. , 1997, The Journal of trauma.
[40] S. Vasikaran. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study , 2009, Osteoporosis International.
[41] A. Parfitt. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. , 2002, Bone.
[42] P. Meunier,et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. , 2000, Bone.
[43] D. Burr,et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. , 2006, Bone.
[44] F. Ongseng,et al. Interpretation and classification of bone scintigraphic findings in stress fractures. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] Vashishith. EFFECTS OF NON-ENZYMATIC GLYCATION ON CANCELLOUS BONE FRAGILITY , 2005 .
[46] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[47] D. Nunamaker. Bucked Shins in Horses , 2000 .
[48] S. Coburn,et al. “Atypical femoral fractures” during bisphosphonate exposure in adult hypophosphatasia , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[49] Jinhu Xiong,et al. Matrix-embedded cells control osteoclast formation , 2011, Nature Medicine.
[50] Michael P. Kelly,et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. , 2010, The New England journal of medicine.
[51] Feng-Sheng Wang,et al. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. , 2008, Endocrinology.
[52] P. Vestergaard,et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene , 2011, Osteoporosis International.
[53] R. Recker,et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. , 2000, The Journal of clinical endocrinology and metabolism.
[54] B. Gruber,et al. Successful treatment of sternal fracture nonunion with teriparatide , 2010, Osteoporosis International.
[55] G. Dalsky,et al. Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[56] D. Burr,et al. Chapter 6 – Principles of Bone Biomechanics , 2006 .
[57] J. Bilezikian,et al. Fragility fractures of the hip and femur: incidence and patient characteristics , 2010, Osteoporosis International.
[58] J. Schneider. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. , 2009, Geriatrics.
[59] S. Ott,et al. Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures , 2011, Osteoporosis International.
[60] J. Zerwekh,et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.
[61] D. Vashishth,et al. Effects of non-enzymatic glycation on cancellous bone fragility. , 2007, Bone.
[62] B. Abrahamsen. Atypical femur fractures: Refining the clinical picture , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[63] J. Schilcher,et al. Atypical fractures do not have a thicker cortex , 2012, Osteoporosis International.
[64] W. Ambrosius,et al. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. , 1997, Bone.
[65] S. Teitelbaum,et al. Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series , 2009, Calcified Tissue International.
[66] S. Montgomery,et al. National data of 6409 Swedish inpatients with femoral shaft fractures: stable incidence between 1998 and 2004. , 2009, Injury.
[67] P. Fratzl,et al. Effects of 3‐ and 5‐Year Treatment With Risedronate on Bone Mineralization Density Distribution in Triple Biopsies of the Iliac Crest in Postmenopausal Women , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[68] P. Clézardin,et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. , 2002, Cancer research.
[69] C. Christiansen,et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. , 2003, Bone.
[70] S. Schneeweiss,et al. Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[71] M. Goddard,et al. Atraumatic bilateral femur fracture in long-term bisphosphonate use. , 2009, Orthopedics.
[72] S. Cremers,et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. , 2010, The Journal of clinical endocrinology and metabolism.
[73] P. Fratzl,et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. , 2001, Bone.
[74] T. Howe,et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. , 2007, The Journal of bone and joint surgery. British volume.
[75] Matthew J. Silva,et al. Healing of non-displaced fractures produced by fatigue loading of the mouse ulna. , 2010, Bone.
[76] E. Donnelly,et al. Atypical femoral fractures: epidemiology, etiology, and patient management , 2012, Current opinion in supportive and palliative care.
[77] D. Glennon. Subtrochanteric stress fractures in six patients on long term bisphosphonate therapy: A case series , 2009 .
[78] W. Busse. Atypical Femoral Fractures and Bone Turnover , 2011 .
[79] S. Silverman,et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[80] S. Ilgan,et al. Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report , 2007, Archives of Orthopaedic and Trauma Surgery.
[81] R. Eastell,et al. Subtrochanteric and diaphyseal fractures in patients during long-term alendronate treatment: Expanded and extended national register based cohort study , 2010 .
[82] F. Berger,et al. Stress fractures in the lower extremity. The importance of increasing awareness amongst radiologists. , 2007, European journal of radiology.
[83] S. Cummings,et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.
[84] P. Dayer,et al. Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates , 2009, Drug safety.
[85] Richard Weinkamer,et al. Effect of Temporal Changes in Bone Turnover on the Bone Mineralization Density Distribution: A Computer Simulation Study , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[86] A. Boskey,et al. Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality , 2012, Arthritis Research & Therapy.
[87] C. Cooper,et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. , 2003, Bone.
[88] C. Cooper,et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report , 2010, Osteoporosis International.
[89] Lynn Wei,et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. , 1997, The Journal of clinical investigation.
[90] P. Sambrook,et al. Osteoporosis and the osteoporosis of rheumatic diseaes , 2006 .
[91] C Milgrom,et al. Aging and matrix microdamage accumulation in human compact bone. , 1995, Bone.
[92] N. Napoli,et al. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. , 2006, The New England journal of medicine.
[93] D. Mellström,et al. Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.
[94] P. Rose. Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women , 2012 .
[95] F. Melsen,et al. Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. , 1999, Bone.
[96] M. Malice,et al. Effects of Alendronate on Bone Quality and Remodeling in Glucocorticoid‐Induced Osteoporosis: A Histomorphometric Analysis of Transiliac Biopsies , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[97] J. Rütt,et al. Subtrochanteric stress fracture of the femur following total knee arthroplasty. , 1997, The Journal of arthroplasty.
[98] D. Burr,et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate , 2009, Osteoporosis International.
[99] F. McKiernan. Atypical femoral diaphyseal fractures documented by serial DXA. , 2010, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[100] A. Wetterwald,et al. Dissociation of Angiogenesis and Osteoclastogenesis During Endochondral Bone Formation in Neonatal Mice , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[101] L. Devy,et al. Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.
[102] F. Hsiao,et al. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. , 2011, Clinical therapeutics.
[103] O. Dekkers,et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. , 2011, Bone.
[104] K. Michaëlsson,et al. Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.
[105] G. Matheson,et al. Exercise-Induced Stress Injuries to the Femur , 1993, International journal of sports medicine.
[106] I. McCall,et al. Incidence of serious side effects with intravenous bisphosphonate: a clinical audit. , 2012, QJM : monthly journal of the Association of Physicians.
[107] M. Edwards,et al. Alendronate-related femoral diaphysis fracture—what should be done to predict and prevent subsequent fracture of the contralateral side? , 2010, Osteoporosis International.
[108] G. Hooper,et al. Atypical subtrochanteric fractures, bisphosphonates, blinded radiological review , 2012, ANZ journal of surgery.
[109] F. McKiernan,et al. Severely suppressed bone turnover and atypical skeletal fragility. , 2008, The Journal of clinical endocrinology and metabolism.
[110] J. Magaziner,et al. The association of race, gender, and comorbidity with mortality and function after hip fracture. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.
[111] J. Compston. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw , 2011, Osteoporosis International.
[112] F Melsen,et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. , 2002, Bone.
[113] A. Sayed-Noor,et al. Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy , 2009, Clinical orthopaedics and related research.
[114] M. Somford,et al. Long-Term Alendronate Use Not without Consequences? , 2010, International journal of rheumatology.
[115] M. Soveyd,et al. INCIDENCE OF HIP FRACTURE IN SHIRAZ , 2005 .
[116] P. Delmas,et al. Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long‐Term Bisphosphonates: A Bone Biopsy Study , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[117] D. Burr,et al. Risedronate treatment does not increase microdamage in the canine femoral neck. , 1995, Bone.
[118] G. Németh,et al. Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients. , 2009, Injury.
[119] L J Donaldson,et al. Incidence of fractures in a geographically defined population. , 1990, Journal of epidemiology and community health.
[120] A. S. Stephens,et al. Temporal pattern of gene expression and histology of stress fracture healing. , 2010, Bone.
[121] D. Burr,et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. , 2001, Bone.
[122] B. Ettinger,et al. Clinical correlates of atypical femoral fracture. , 2012, Bone.
[123] B. Mitlak,et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). , 2005, The Journal of bone and joint surgery. American volume.
[124] P. Delmas,et al. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra , 2008, Osteoporosis International.
[125] K. Yang,et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures , 2011 .
[126] P Zioupos,et al. The role of collagen in the declining mechanical properties of aging human cortical bone. , 1999, Journal of biomedical materials research.
[127] G. Holt,et al. Gender differences in epidemiology and outcome after hip fracture: evidence from the Scottish Hip Fracture Audit. , 2008, The Journal of bone and joint surgery. British volume.
[128] C. Shin,et al. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry , 2013, Osteoporosis International.
[129] M. Safford,et al. Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. , 2012, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[130] P. Muir,et al. In vivo matrix microdamage in a naturally occurring canine fatigue fracture. , 1999, Bone.
[131] P. Fratzl,et al. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long‐term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long‐term extension (FLEX) , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[132] W. Park,et al. Atypical Subtrochanteric Femur Fracture in Patient with Metastatic Breast Cancer Treated with Zoledronic Acid , 2012, Journal of breast cancer.
[133] M. Bouxsein,et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. , 2006, Bone.
[134] T. Howe,et al. Femoral Cortical Stress Lesions in Long-Term Bisphosphonate Therapy: A Herald of Impending Fracture? , 2010, Journal of orthopaedic trauma.
[135] J. Mink,et al. Imaging of stress injuries to bone. Radiography, scintigraphy, and MR imaging. , 1997, Clinics in sports medicine.
[136] M. Westmore,et al. Raloxifene, Estrogen, and Alendronate Affect the Processes of Fracture Repair Differently in Ovariectomized Rats , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[137] D. Burr,et al. Three Years of Alendronate Treatment Results in Similar Levels of Vertebral Microdamage as After One Year of Treatment , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[138] D. Vashishth,et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. , 2001, Bone.
[139] D. Burr,et al. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[140] Matthew J Silva,et al. fracture healing : Fatigue loading of the rat ulna induces upregulation in expression of osteogenic and angiogenic genes that mimic the intramembranous portion of fracture repair , 2009 .
[141] T. Howe,et al. Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. , 2011, Singapore medical journal.
[142] T. Bhattacharyya,et al. Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996–2007 , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[143] B. Abrahamsen. Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low , 2011, Evidence Based Medicine.
[144] A. Sayed-Noor,et al. Subtrochanteric displaced insufficiency fracture after long‐term alendronate therapy—a case report , 2008, Acta orthopaedica.
[145] B. Jobke. Giant osteoclast formation and long-term oral bisphosphonate therapy. , 2009, The New England journal of medicine.
[146] J. Lee. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium , 2009, International journal of rheumatic diseases.
[147] A. Adams,et al. Ten-year hip fracture incidence rate trends in a large California population, 1997–2006 , 2012, Osteoporosis International.
[148] C. M. Agrawal,et al. Age-related changes in the collagen network and toughness of bone. , 2002, Bone.
[149] A. Kung,et al. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates , 2009, BMJ Case Reports.
[150] N. Napoli,et al. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies , 2010, Osteoporosis International.
[151] M. Seibel,et al. Atypical femoral fractures and bisphosphonate use. , 2010, The New England journal of medicine.
[152] O. Böstman,et al. Population Based Epidemiologic and Morphologic Study of Femoral Shaft Fractures , 2000, Clinical orthopaedics and related research.
[153] D. Burr,et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. , 2007, Bone.
[154] M. Swiontkowski. Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study , 2010 .
[155] Jiliang Li,et al. Low‐intensity pulsed ultrasound and nonsteroidal anti‐inflammatory drugs have opposing effects during stress fracture repair , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[156] D. Burr,et al. Alendronate Reduces Bone Toughness of Ribs without Significantly Increasing Microdamage Accumulation in Dogs Following 3 Years of Daily Treatment , 2008, Calcified Tissue International.
[157] G. Mclauchlan,et al. Epidemiology of fractures in 15,000 adults: the influence of age and gender. , 1998, The Journal of bone and joint surgery. British volume.
[158] Yuh‐Min Cheng,et al. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report , 2012, Menopause.
[159] E. Shane. Evolving data about subtrochanteric fractures and bisphosphonates. , 2010, The New England journal of medicine.
[160] J. Zerwekh,et al. Unusual mid‐shaft fractures during long‐term bisphosphonate therapy , 2010, Clinical endocrinology.
[161] P. Fratzl,et al. Bone Material Properties in Trabecular Bone From Human Iliac Crest Biopsies After 3‐ and 5‐Year Treatment With Risedronate , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[162] M. Soveid,et al. Incidence of hip fracture in Shiraz, Iran , 2005, Osteoporosis International.
[163] H. Genant,et al. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double‐blind study of 102 postmenopausal women with distal radial fractures , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[164] G. Fraschini,et al. Osteoporosis International , 2002, Osteoporosis International.
[165] L. Melton,et al. Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984–2007 , 2012, Osteoporosis International.
[166] A. Buhr,et al. Incidence of Fractures in Persons over 35 Years of Age , 1964, British journal of preventive & social medicine.
[167] M. McDonald,et al. Bisphosphonate treatment and fracture repair , 2007 .
[168] E. Fishman,et al. Computed tomography of stress fractures. , 1986, Journal of computer assisted tomography.
[169] M. Mawatari,et al. Bipolar hip arthroplasty for subtrochanteric femoral nonunion in an adult with autosomal dominant osteopetrosis type II , 2011, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.
[170] A. Boskey,et al. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women , 2009, Osteoporosis International.
[171] D. Lorich,et al. Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.
[172] M. Gaeta,et al. CT and MR imaging findings in athletes with early tibial stress injuries: comparison with bone scintigraphy findings and emphasis on cortical abnormalities. , 2005, Radiology.
[173] R. Eastell,et al. Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register‐Based National Cohort Study , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[174] C. Milgrom,et al. Musculoskeletal fatigue and stress fractures , 2000 .
[175] J. Lee,et al. Stress fractures: MR imaging. , 1988, Radiology.
[176] D. Lorich,et al. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. , 2008, The New England journal of medicine.
[177] A. Newberg,et al. Imaging of stress fractures in the athlete. , 2002, Radiologic clinics of North America.
[178] Kristien Verheyen,et al. Exercise distance and speed affect the risk of fracture in racehorses. , 2006, Bone.
[179] J. Glowacki,et al. Correlation of plain radiographic indices of the hip with quantitative bone mineral density , 2007, Osteoporosis International.
[180] J. Cauley,et al. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. , 2012, The Journal of clinical endocrinology and metabolism.
[181] P. Fratzl,et al. Constant mineralization density distribution in cancellous human bone. , 2003, Bone.
[182] S. Das De,et al. A rational approach to management of alendronate-related subtrochanteric fractures. , 2010, The Journal of bone and joint surgery. British volume.
[183] A. Giusti,et al. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. , 2010, Bone.
[184] O. Johnell,et al. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture , 2004, Osteoporosis International.
[185] R. Jay,et al. Spontaneous femoral shaft fracture after long-term alendronate. , 2009, Age and ageing.
[186] S. Bukata,et al. Teriparatide May Accelerate Healing in Delayed Unions of Type III Odontoid Fractures: A Report of 3 Cases , 2010, Journal of spinal disorders & techniques.
[187] A. Parfitt,et al. Perspective: Quantifying Osteoblast and Osteocyte Apoptosis: Challenges and Rewards , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[188] M. Whyte. Atypical Femoral Fractures, Bisphosphonates, and Adult Hypophosphatasia , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[189] T. Perneger,et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. , 2012, Archives of internal medicine.
[190] S. Gupta,et al. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? , 2012, Singapore medical journal.
[191] R. Weinstein,et al. Connexin 43 Is Required for the Anti‐Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts In Vivo , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[192] S. B. Jones,et al. The Superiority of Magnetic Resonance Imaging in Differentiating the Cause of Hip Pain in Endurance Athletes , 1996, The American journal of sports medicine.
[193] C. Moran,et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. , 2012, The Journal of bone and joint surgery. British volume.
[194] J. Schilcher,et al. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate , 2009, Acta orthopaedica.
[195] K. Bennell,et al. Ground reaction forces, bone characteristics, and tibial stress fracture in male runners. , 1999, Medicine and science in sports and exercise.
[196] V. Kalscheur,et al. Effect of short‐term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[197] C. Grimsrud,et al. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. , 2012, Bone.
[198] P. Ebeling,et al. Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. , 2010, The Journal of clinical endocrinology and metabolism.
[199] W. O'Fallon,et al. Fracture Incidence in Olmsted County, Minnesota: Comparison of Urban with Rural Rates and Changes in Urban Rates Over time , 1999, Osteoporosis International.
[200] I. Harris,et al. Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy , 2010, Clinical orthopaedics and related research.
[201] Mark Johnson. Faculty of 1000 evaluation for Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. , 2010 .
[202] V. Novack,et al. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. , 2004, Bone.
[203] S M Jorgensen,et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. , 2006, Bone.
[204] J. Babb,et al. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. , 2012, AJR. American journal of roentgenology.
[205] M. Seibel,et al. Looking beyond low bone mineral density: Multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy , 2007, Journal of endocrinological investigation.
[206] S. Ikehara,et al. Prevention of corticosteroid-induced osteonecrosis in rabbits by intra-bone marrow injection of autologous bone marrow cells. , 2008, Rheumatology.
[207] N. Tejwani,et al. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. , 2009, The Journal of bone and joint surgery. American volume.
[208] P. Chavassieux,et al. Bilateral Fractures of the Femur Diaphysis in a Patient With Rheumatoid Arthritis on Long‐Term Treatment With Alendronate: Clues to the Mechanism of Increased Bone Fragility , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[209] P. Ebeling,et al. An atypical subtrochanteric femoral fracture from pycnodysostosis: A lesson from nature , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[210] T. Keaveny,et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. , 2005, Bone.
[211] D. Kubek,et al. Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs , 2011, Osteoporosis International.
[212] S. Goto,et al. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats , 2009, Journal of Bone and Mineral Metabolism.
[213] G. H. Nancollas,et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. , 2006, Bone.
[214] S. Silverman,et al. Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[215] M. Hongo,et al. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series , 2012, Journal of Bone and Mineral Metabolism.
[216] A. Mullaji,et al. Low-energy subtrochanteric fractures in elderly patients: results of fixation with the sliding screw plate. , 1993, The Journal of trauma.
[217] J. Li,et al. Bisphosphonate Treatment Suppresses Not Only Stochastic Remodeling but Also the Targeted Repair of Microdamage , 2001, Calcified Tissue International.
[218] J. Chandler,et al. Incidence and demography of femur fractures with and without atypical features , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[219] W. Murphy,et al. Postmenopausal osteoporosis: A heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients , 1982 .
[220] M. Maravic,et al. Subtrochanteric/femoral shaft Versus hip fractures: Incidences and identification of risk factors , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[221] S. Wimalawansa,et al. Case Series: Atypical Subtrochanteric Femoral Fractures After Potent Anti-Resorptive Therapy , 2011 .
[222] D. Mancini,et al. Discontinuing Antiresorptive Therapy One Year after Cardiac Transplantation: Effect on Bone Density and Bone Turnover , 2006, Transplantation.
[223] R. Chisin. The Role of Various Imaging Modalities in Diagnosing Stress Fractures , 2000 .
[224] P. C. Mohan,et al. Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy , 2012, European Radiology.
[225] J. Jelinek,et al. Low‐Energy Femoral Fractures Associated With Long‐Term Bisphosphonate Use in a Rehabilitation Setting: A Case Series , 2010, PM & R : the journal of injury, function, and rehabilitation.
[226] Kosaku Kurata,et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression , 2011, Nature Medicine.
[227] D. Burr,et al. Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than with risedronate , 2006 .
[228] M. Seibel,et al. Bisphosphonate use and femoral fractures in older women. , 2011, JAMA.